Abstract
Naoxintong (NXT), a Chinese Materia Medica standardized product, extracted from 16 various kinds of Chinese traditional herbal medicines including Salvia miltiorrhiza, Angelica sinennsis, Astragali Radix, is clinically effective in treating atherosclerosisrelated diseases. Here, we tested the hypothesis that the anti-atherosclerosis effects of NXT might be mediated by suppressing maturation of dendritic cells (DCs) in a mice model of atherosclerosis. LDLR-/- mice fed a high-fat diet were treated with placebo, NXT (0.7g/kg/d, oral diet) or simvastatin (100mg/kg/d, oral diet) for 8 weeks, respectively. NXT treatment significantly reduced plasma triglyceride (112±18 mg/dl vs. 192±68 mg/dl, P<0.05) and total cholesterol (944±158 mg/dl vs. 1387±208 mg/dl, P<0.05) compared to placebo treatment. Vascular lesions were significantly smaller and macrophage content and amount of DCs in plaques were significantly less in NXT and simvastatin groups than in placebo group (all P<0.05). In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. In conclusion, NXT protects against atherosclerosis through lipid-lowering and inhibiting DCs maturation in this mice model of atherosclerosis.
Keywords: Atherosclerosis, naoxintong, dendritic cell.
Current Pharmaceutical Design
Title:Naoxintong Protects against Atherosclerosis through Lipid-lowering and Inhibiting Maturation of Dendritic Cells in LDL Receptor Knockout Mice fed a High-fat Diet
Volume: 19 Issue: 33
Author(s): Xueting Jin, Junbo Ge, Aijun Sun, Kai Hu, Yunzeng Zou, Keqiang Wang, Lifu Jia, Tao Zhao, Buchang Zhao, Jingjing Zhao, Shuxia Fan, Hangtian Zhao, Cong Wang, Xiangwei Liu, Xin Ma, Shijun Wang and Hong Zhu
Affiliation:
Keywords: Atherosclerosis, naoxintong, dendritic cell.
Abstract: Naoxintong (NXT), a Chinese Materia Medica standardized product, extracted from 16 various kinds of Chinese traditional herbal medicines including Salvia miltiorrhiza, Angelica sinennsis, Astragali Radix, is clinically effective in treating atherosclerosisrelated diseases. Here, we tested the hypothesis that the anti-atherosclerosis effects of NXT might be mediated by suppressing maturation of dendritic cells (DCs) in a mice model of atherosclerosis. LDLR-/- mice fed a high-fat diet were treated with placebo, NXT (0.7g/kg/d, oral diet) or simvastatin (100mg/kg/d, oral diet) for 8 weeks, respectively. NXT treatment significantly reduced plasma triglyceride (112±18 mg/dl vs. 192±68 mg/dl, P<0.05) and total cholesterol (944±158 mg/dl vs. 1387±208 mg/dl, P<0.05) compared to placebo treatment. Vascular lesions were significantly smaller and macrophage content and amount of DCs in plaques were significantly less in NXT and simvastatin groups than in placebo group (all P<0.05). In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. In conclusion, NXT protects against atherosclerosis through lipid-lowering and inhibiting DCs maturation in this mice model of atherosclerosis.
Export Options
About this article
Cite this article as:
Jin Xueting, Ge Junbo, Sun Aijun, Hu Kai, Zou Yunzeng, Wang Keqiang, Jia Lifu, Zhao Tao, Zhao Buchang, Zhao Jingjing, Fan Shuxia, Zhao Hangtian, Wang Cong, Liu Xiangwei, Ma Xin, Wang Shijun and Zhu Hong, Naoxintong Protects against Atherosclerosis through Lipid-lowering and Inhibiting Maturation of Dendritic Cells in LDL Receptor Knockout Mice fed a High-fat Diet, Current Pharmaceutical Design 2013; 19 (33) . https://dx.doi.org/10.2174/1381612811319330008
DOI https://dx.doi.org/10.2174/1381612811319330008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential
Current Medicinal Chemistry Functional Components from Nature-Derived Drugs for the Treatment of Rheumatoid Arthritis
Current Drug Targets Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Dipeptidyl Peptidase IV Inhibitors: The Next Generation of New Promising Therapies for the Management of Type 2 Diabetes
Current Topics in Medicinal Chemistry Promising Therapies in Sickle Cell Disease
Cardiovascular & Hematological Disorders-Drug Targets The Apoptotic Pathway as a Therapeutic Target in Sepsis
Current Drug Targets Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Signal Transduction of the Aging Innate Immune System
Current Immunology Reviews (Discontinued) PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Current Drug Targets Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Opinion Paper: A Cognitive-cultural Segregation and the Three Stages of Aging
Current Aging Science